通过药物基因组学改变药物监测:朝着个性化的风险管理
Claire Spahn1, Nanase Toda2, Blaine Groat3
1Department of Pharmacy, Stanford Health Care, Stanford, California, USA.
Clinical pharmacology and therapeutics
|October 28, 2025
概括
药物监测计划应整合药物基因组数据,以提高药物安全性. 使用AI和ML分析遗传标记可以揭示洞察力,减少药物不良反应并改善患者的治疗结果.
科学领域:
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
- 计算生物学 计算生物学
背景情况:
- 药物的安全性依赖于药物监测,以检测市场后的药物不良反应 (ADRs).
- 副作用导致严重的健康后果,包括住院治疗和死亡率.
- 药物遗传标记解释了特异性ADR,但尚未成为报告中的标准.
研究的目的:
- 审查当前的药物监测和药物基因组实践.
- 倡导将药物基因组学纳入药物监测.
- 突出AI和ML在分析药物安全性药物基因组数据方面的潜力.
主要方法:
- 药物监测和药物基因组整合的文献综述.
- 分析药物遗传学在ADR中的作用.
- 在药物基因组数据分析中讨论AI/ML应用.
主要成果:
- 药基因组数据可以解释和预测ADRs.
- 使用药物基因组学的精准医学方法可以改善临床结果.
- 人工智能和机器学习为复杂的遗传数据提供了先进的分析能力.
结论:
- 将药物基因组学纳入药物监测是提高药物安全性的关键.
- 药基因组测试为个性化处方提供了有价值的数据.
- 人工智能和机器学习可以从药物基因组数据中获得更深入的见解,从而为公共卫生带来好处.
相关概念视频
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Dosage Regimen: Individualization
165
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
165
Analysis of Population Pharmacokinetic Data
671
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
671
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
397
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
397
Dosage Regimens: Partial Pharmacokinetic Parameters
147
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
147


